Ahsan C H, Renwick A G, Waller D G, Challenor V F, George C F, Amanullah M
Clinical Pharmacology Group, University of Southampton, United Kingdom.
Clin Pharmacol Ther. 1993 Sep;54(3):329-38. doi: 10.1038/clpt.1993.155.
The pharmacokinetics of nifedipine capsules was investigated in healthy young Caucasian and South Asian subjects. Both the area under the plasma concentration-time curve (AUC) and terminal half-life of nifedipine were significantly higher in South Asians compared with Caucasian subjects after single oral doses of 10 and 20 mg. The AUC and half-life values of the nitropyridine metabolite were also higher in South Asians than in Caucasian subjects. The serum protein binding of nifedipine was similar in the two groups. The pharmacokinetics were essentially linear in both Caucasian subjects (0 to 30 mg; n = 27) and South Asians (0 to 20 mg; n = 16). There was no indication of a separate subgroup of Caucasian subjects with high AUC values equivalent to the poor metabolizers reported previously. Pharmacodynamic modeling for South Asians gave estimates comparable to those previously reported in Caucasian subjects. Patients of South Asian origin may require lower doses of nifedipine.
在健康的年轻白种人和南亚受试者中研究了硝苯地平胶囊的药代动力学。单次口服10毫克和20毫克剂量后,南亚受试者的血浆浓度-时间曲线下面积(AUC)和硝苯地平的终末半衰期均显著高于白种人受试者。南亚受试者中硝基吡啶代谢物的AUC和半衰期值也高于白种人受试者。两组中硝苯地平的血清蛋白结合率相似。白种人受试者(0至30毫克;n = 27)和南亚受试者(0至20毫克;n = 16)的药代动力学基本呈线性。没有迹象表明白种人受试者中有一个单独的亚组,其AUC值高,相当于先前报道的代谢不良者。对南亚受试者的药效学建模给出的估计值与先前在白种人受试者中报道的相当。南亚裔患者可能需要较低剂量的硝苯地平。